Biogennix received FDA 510(k) clearance to market Agilon™ bone graft material, reportedly the only collagen-enhanced synthetic graft that is packaged in an open-barrel syringe. Agilon is available in 3cc, 6cc and 12cc sizes, and U.S. distribution is underway.
Agilon addresses surgeon demand for a collagen-enhanced product, complementing the company’s existing Morpheus™ and osteoSPAN™ products. It features TrelCor™ material that is engineered to mimic human cancellous bone. Interconnected pores average 500 microns (µ) in size, and all surfaces throughout the porosity are covered by 4 microns of calcium phosphate. Studies indicate that TrelCor allows Biogennix’s bone graft material to become incorporated into a bone fusion while gradually resorbing over a 6-12 month period.
Biogennix received FDA 510(k) clearance to market Agilon™ bone graft material, reportedly the only collagen-enhanced synthetic graft that is packaged in an open-barrel syringe. Agilon is available in 3cc, 6cc and 12cc sizes, and U.S. distribution is underway.
Agilon addresses surgeon demand for a collagen-enhanced product, complementing the...
Biogennix received FDA 510(k) clearance to market Agilon™ bone graft material, reportedly the only collagen-enhanced synthetic graft that is packaged in an open-barrel syringe. Agilon is available in 3cc, 6cc and 12cc sizes, and U.S. distribution is underway.
Agilon addresses surgeon demand for a collagen-enhanced product, complementing the company’s existing Morpheus™ and osteoSPAN™ products. It features TrelCor™ material that is engineered to mimic human cancellous bone. Interconnected pores average 500 microns (µ) in size, and all surfaces throughout the porosity are covered by 4 microns of calcium phosphate. Studies indicate that TrelCor allows Biogennix’s bone graft material to become incorporated into a bone fusion while gradually resorbing over a 6-12 month period.
Copy to clipboard 
